title: DNA vaccine with α-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells.
abstract: DNA vaccines contribute to a promising new approach for the generation of cytotoxic T lymphocytes (CTL). DNA vaccines do have several disadvantages, including poor immunogenicity and oncogene expression. We used the natural killer T-cell (NKT) ligand α-galactosylceramide (α-GalCer) as an adjuvant to prime initial DNA vaccination; and used the potent immune-stimulatory tumor antigen-expressing dendritic cells (DCs) as a booster vaccination. A DNA vaccine expressing human papillomavirus (HPV) type 16 E7 (pcDNA3-CRT/E7) was combined with α-GalCer at the prime phase, and generated a higher number of E7-specific CD8(+) T-cells in vaccinated mice than vaccine used at boost phase. Therefore, priming with a DNA vaccine in the presence of α-GalCer and boosting with E7-pulsed DC-1 led to a significant enhancement of E7-specific CD8(+) effector and memory T-cells as well as significantly improved therapeutic and preventive effects against an E7-expressing tumor model (TC-1) in vaccinated mice. Our findings suggested that the potency of a DNA vaccine combined with α-GalCer could be further enhanced by boosting with an antigen-expressing DC-based vaccine to generate anti-tumor immunity.
authors.affiliation: Department of Anatomy, Chung-Ang University, College of Medicine, Seoul, Republic of Korea. kimdj@cau.ac.kr
authors.forename: Daejin
authors.initials: D
authors.lastname: Kim
authors.forename: Chien-Fu
authors.initials: CF
authors.lastname: Hung
authors.forename: T-C
authors.initials: TC
authors.lastname: Wu
authors.forename: Yeong-Min
authors.initials: YM
authors.lastname: Park
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology*; D045744:Cell Line, Tumor; D016207:Cytokines / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D005699:Galactosylceramides / Q000008:administration & dosage* / Q000276:immunology; D007117:Immunization, Secondary; D051379:Mice; D008810:Mice, Inbred C57BL; D009374:Neoplasms, Experimental / Q000276:immunology / Q000517:prevention & control; D050725:Papillomavirus E7 Proteins / Q000276:immunology; D013154:Spleen / Q000166:cytology; D019444:Vaccines, DNA / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D016207:Cytokines; D005699:Galactosylceramides; D050725:Papillomavirus E7 Proteins; D019444:Vaccines, DNA; C493154:alpha-galactosylceramide; C059731:oncogene protein E7, Human papillomavirus type 16
references.citation: Life Sci. 1997;60(3):163-72
references.pmid: 9000640
references.citation: Ann N Y Acad Sci. 1995 Nov 27;772:30-9
references.pmid: 8546411
references.citation: Cancer Res. 2000 Jun 1;60(11):2810-5
references.pmid: 10850419
references.citation: Vaccine. 2009 Sep 4;27(40):5450-9
references.pmid: 19622402
references.citation: Nat Biotechnol. 2000 Sep;18(9):974-9
references.pmid: 10973219
references.citation: J Exp Med. 2007 Oct 29;204(11):2641-53
references.pmid: 17923500
references.citation: J Exp Med. 2003 Jul 21;198(2):267-79
references.pmid: 12874260
references.citation: Cancer Res. 2001 May 1;61(9):3698-703
references.pmid: 11325841
references.citation: Nat Immunol. 2002 Sep;3(9):867-74
references.pmid: 12154358
references.citation: Vaccine. 2009 Oct 19;27(44):6210-6
references.pmid: 19699331
references.citation: J Intern Med. 2003 Apr;253(4):402-10
references.pmid: 12653868
references.citation: J Clin Invest. 2001 Sep;108(5):669-78
references.pmid: 11544272
references.citation: Cancer Sci. 2009 Jun;100(6):1092-8
references.pmid: 19302288
references.citation: J Immunol. 1998 Oct 1;161(7):3271-81
references.pmid: 9759842
references.citation: Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):11088-93
references.pmid: 15258286
references.citation: Blood. 2007 Sep 15;110(6):2013-9
references.pmid: 17581919
references.citation: Immunology. 2004 May;112(1):117-25
references.pmid: 15096191
references.citation: Annu Rev Immunol. 2000;18:927-74
references.pmid: 10837079
references.citation: Leukemia. 1999 May;13(5):653-63
references.pmid: 10374867
references.citation: Clin Cancer Res. 2005 Nov 15;11(22):8114-21
references.pmid: 16299244
references.citation: Vaccine. 2006 Mar 24;24(14):2575-84
references.pmid: 16420967
references.citation: J Immunol. 2009 Feb 15;182(4):2492-501
references.pmid: 19201905
references.citation: Vaccine. 2008 Mar 28;26(15):1807-16
references.pmid: 18329757
references.citation: Infect Immun. 2004 Dec;72(12):6945-50
references.pmid: 15557616
references.citation: Immunol Rev. 2008 Apr;222:43-69
references.pmid: 18363994
references.citation: Cancer Immunol Immunother. 2004 Mar;53(3):240-8
references.pmid: 14685779
references.citation: Methods Mol Biol. 2008;423:19-33
references.pmid: 18370188
references.citation: IDrugs. 2003 Dec;6(12):1155-64
references.pmid: 14666426
references.citation: J Immunol. 2000 Sep 1;165(5):2850-8
references.pmid: 10946318
references.citation: J Exp Med. 2002 Mar 4;195(5):617-24
references.pmid: 11877484
references.citation: Science. 1997 Nov 28;278(5343):1626-9
references.pmid: 9374463
references.citation: Eur J Immunol. 1993 Sep;23(9):2242-9
references.pmid: 7690326
references.citation: Vaccine. 2008 Feb 6;26(6):753-61
references.pmid: 18191308
references.citation: J Exp Med. 1998 Oct 19;188(8):1529-34
references.pmid: 9782130
references.citation: Nat Rev Immunol. 2003 Aug;3(8):630-41
references.pmid: 12974478
references.citation: Int Immunol. 2006 Aug;18(8):1279-83
references.pmid: 16772371
references.citation: Hum Vaccin. 2008 Nov-Dec;4(6):449-52
references.pmid: 18443427
references.citation: Cancer Res. 2000 Feb 15;60(4):1035-42
references.pmid: 10706121
references.citation: Cancer Res. 1996 Jan 1;56(1):21-6
references.pmid: 8548765
references.citation: J Clin Invest. 2005 Sep;115(9):2572-83
references.pmid: 16138194